Ellie Collins
Oxford PharmaGenesis welcomes Christopher Rains on board as our first Non-Executive Director Oxford PharmaGenesis is proud to announce the appointment of Christopher Rains as our first Non-Executive Director, strengthening the Board with over 30 years of experience in the pharmaceutical industry. A former executive at Takeda, Shire and AstraZeneca, Chris brings unparalleled knowledge and expertise […]
Read More
For the fourth year running, media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in its Agency 100 report – the annual definitive ‘who’s who’ ranking of the healthcare sector’s top marketing firms in North America. A key indicator of the sector’s health, the hotly anticipated report spotlights the most accomplished players in […]
Read More
Author: Kate Haynes – Communications Director at Oxford PharmaGenesis At Oxford PharmaGenesis, we appreciate the importance of impact and the need for our clients to achieve it. It was therefore serendipitous that the theme of the 2024 Medical Affairs Professional Society (MAPS) European congress was ‘impact’ and how this notoriously elusive goal can be attained […]
Read More
Navigating the narrative: insights from the 20th Annual Meeting of the International Society for Medical Publication Professionals (ISMPP) As medical publication professionals, we are natural storytellers, expertly crafting intricate narratives that transform data into engaging stories and simplifying complex medical concepts for a broader audience. The essence of this skill was a recurring theme at […]
Read More
HEOR and market access are evolving, with changes in HTA, acceleration in the use of RWE and increased reactions to cost-containment measures. We are contributing to conversations about how these changes affect value demonstration strategies. At Oxford PharmaGenesis, we are experts in advising on payer strategy, developing payer evidence and supporting payer evaluation. We understand differences in payer evidence needs, and we know how to create compelling value stories for our clients that achieve powerful results.
Read More
Oxford PharmaGenesis is global, award-winning and independent. Our unique HealthScience approach combines audience insights, best practice in omnichannel communications and proven behaviour change techniques to maximize your impact. From Medical Affairs to Market Access, join us to explore new frontiers.
Read More
Integrated evidence generation planning is more effective than traditional evidence generation planning. It can help pharmaceutical organizations to improve patient care and outcomes.
Read More
The 2024 European meeting of the International Society for Medical Publication Professionals (ISMPP), held on 23–24 January 2024, saw professionals from all areas of medical communications gather in the Novotel London West to shelter from some quintessentially British weather. I started working at Oxford PharmaGenesis only a couple of months before the world locked down […]
Read More
Following an invitation from MAPS (Medical Affairs Professional Society), Oxford PharmaGenesis Communications Director Gary Male has joined the Evidence Generation Focus Area Working Group (FAWG). He will volunteer his time and expertise to help to educate the society’s membership of Medical Affairs professionals about this specialty area.
Read More
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies. The guideline was published today in the non-profit open access journal PLOS Medicine.
Read More